Glomerular C4d deposition indicates in situ classic complement pathway activation, but is not a marker for lupus nephritis activity

Yonsei Medical Journal

Volumn 44, Issue 1, 2003, Pages 75-80

  Kim, Se Hoon ^a   Jeong, Hyeon Joo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Activity index(AI); C4d; Lupus nephritis

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4D; FIBRINOGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE MARKER; FEMALE; GLOMERULUS CAPILLARY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; SCHOOL CHILD;

EID: 0037295851     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2003.44.1.75     Document Type: Article

References (31)

1. Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, Muller-Eberhard HJ, et al. Metabolism of the third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med 1972;287:835-40.
2. Goldstein IM. Clinical applications of complement measurements in rheumatic disease. Am J Med Sci 1975;269:173-82.
3. Morrow WJW, Isenberg DA, Todd-Pokropek A, Parry HF, Snaith ML. Useful laboratory measurements in the management of systemic lupus erythematosus. Q J Med 1982;51:125-38.
4. Valentijn RM, van Overhagen H, Hazvoet HM, Hermans J, Cats A, Daha MR, et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1985;28:904-13.
5. West CD. The complement profile in clinical medicine. Inherited and acquired conditions lowering the serum concentrations of complement components and control proteins. Complement Inflamm 1989;6:49-64.
6. Ricker DM, Hebert LA, Rohde R, Sedmak DD, Lewis EJ, Clough JD. Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborate Study Group. Am J Kidney Dis 1991;18:678-85.
7. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
8. Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 1985;312:1594-9.
9. Senaldi G, Makinde VA, Vergani D, Isenberg DA. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Ann Rheum Dis 1988;47:913-7.
10. Gawryl MS, Chudwin DS, Langlois PF, Lint TF. The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1988;31:188-95.
11. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, et al. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate exacerbations of disease. Arthritis Rheum 1986;29:1085-9.
12. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1988;31:632-41.
13. Porcel JM, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo MJ, Gene T, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 1995;74:283-8.
14. Kerr LD, Adelsberg BR, Spiera H. Complement activation in systemic lupus erythematosus: a marker of inflammation. J Rheumatol 1986;13:313-9.
15. Rother E, Lang B, Coldewey R, Hartung K, Peter HH. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 1993;12:31-5.
16. Negi VS, Aggarwal A, Dayal R, Naik S, Misra R. Complement degradation product C3d in urine: marker of lupus nephritis. J Rheumatol 2000;27:380-3.
17. Muso E, Sekita K, Doi T, Kuwahara T, Yoshida H, Tamura T, et al. Immunopathological correlation between mesangial C3d-deposition and C3d-fixing circulating immune complexes in lupus nephritis. Clin Immunol Immunopathol 1984;32:351-8.
18. Ziccardi RJ. Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol 1981;126:1769-73.
19. Campbell RD, Gagnon J, Porter RR. Amino acid sequence around the thiol and reactive acyl groups of human complement component C4. Biochem J 1981;199:359-70.
20. Press EM, Gagnon J. Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator. Biochem J 1981;199:351-7.
21. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996;50:1464-75.
22. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
23. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983;309:1543-6.
24. Zwirner J, Felber E, Herzog V, Riethmuller G, Feucht HE. Classical pathway of complement activation in normal and disease human glomeruli. Kidney Int 1989;36:1069-77.
25. Kusunoki Y, Itami N, Tochimaru H, Takekoshi Y, Nagasawa S, Yoshiki T. Glomerular deposition of C4 cleavage fragment (C4d) and C4-binding protein in idiopathic membranous glomerulonephritis. Nephron 1989;51:17-9.
26. McCluskey RT. Lupus nephritis. In: Summers SC, editor. Kidney Pathology: decennial. New York: Appelton & Lange; 1975. p.456-9.
27. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow E. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
28. Morel-Maroger L, Mery JP, Droz D, Godin M, Verroust P, Kourilsky O, et al. The course of lupus nephritis: contribution of serial renal biopsies. Adv Nephrol Necker Hosp 1976;6:79-118.
29. Collins AB, Schneeberger EE, Pascual MA, Saidman SL, Williams WW, Tolkoff-Rubin T, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999;10:2208-14.
30. Abraham MA, Korula A, Jayakrishnan K, John GT, Thomas PP, Jacob CK. Prognostic factors in diffuse proliferative lupus nephritis. J Assoc Physicians India 1999;47:862-5.
31. Mitjavila F, Pac V, Moga I, Poveda R, Vidaller A, Carrera M, et al. Clinicopathological correlations and prognostic factors in lupus nephritis. Clin Exp Rheumatol 1997;15:625-31.